Related Experiment Video
Updated: May 20, 2026
23:06
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
New treatment options for multidrug-resistant tuberculosis
Stephen K Field1, Dina Fisher, Julie M Jarand
1Health Science Centre, 3330 Hospital Dr. NW, Calgary, Alberta, Canada. sfield@ucalgary.ca
Therapeutic Advances in Respiratory Disease
|July 6, 2012
Summary
Tuberculosis (TB) treatment faces challenges from drug-resistant Mycobacterium tuberculosis (MTB) strains, necessitating new drugs and strategies. Research explores novel compounds and management approaches for extensively drug-resistant TB.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Tuberculosis (TB) remains a significant global health issue, causing millions of deaths annually.
- Drug resistance in Mycobacterium tuberculosis (MTB) strains, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms, complicates treatment and leads to high mortality.
- Inadequate resources, treatment costs, long regimens, and adverse drug effects contribute to treatment failures and the propagation of resistant strains.
Purpose of the Study:
- To highlight the urgent need for novel therapeutic agents against drug-resistant TB.
- To review current strategies for managing complex TB resistance profiles.
- To discuss promising new drug candidates in clinical development.
Main Methods:
- Review of global TB resistance data from the World Health Organization.
- Analysis of challenges in treating drug-resistant TB.
- Overview of existing and emerging anti-TB drug classes and treatment strategies.
Main Results:
- A substantial percentage of new TB cases exhibit resistance to at least one drug, with significant proportions of MDR and XDR-TB globally.
- Current treatment options are often ineffective against extensively drug-resistant strains.
- Several novel drug classes, including oxazolidinones, diarylquinolines, and benzothiazinones, show promise in ongoing clinical trials.
Conclusions:
- There is a critical need for new drugs to combat resistant TB strains and improve treatment outcomes.
- Innovative management strategies using existing drugs are being explored for short-term relief.
- The development pipeline for novel anti-TB medications offers hope for future treatment of complex resistance profiles.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:31Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...